Pharmaceutical intermediates
Deucravacitinib Intermediates
9 pharmaceutical intermediates for Deucravacitinib. Indication: Plaque Psoriasis; Psoriasis.
About Deucravacitinib
- Originator
- Bristol Myers Squibb
- Indication
- Plaque Psoriasis; Psoriasis
- Approved Date
- 09/09/2022
- NCE Patent
- 09/09/2027
- DS/DP
- 11/07/2033
Available intermediates
9 intermediates currently listed for Deucravacitinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| Ethyl 4,6-dichloropyrridazine-3-carboxylate | 679406-03-2 | / | / |
| Methyl 4,6-dichloropyridazine-3-carboxylate | 372118-01-9 | / | / |
| 2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)aniline | 1609394-10-6 | / | / |
| 4,6-dichloro-N-trideuteromethylpyridazine-3 -carboxamide | 1609393-89-6 | / | / |
| 4,6-dihydroxypyridazine-3-carboxylicacid | 1442437-21-9 | / | / |
| ethyl 4,6-dihydroxypyridazine-3-carboxylate | 1352925-63-3 | / | / |
| Methyl 4,6-dihydroxypyridazine-3-carboxylate | 372118-00-8 | / | / |
| 4,6-Dichloro-3-pyridazinecarboxylic acid, lithium salt | 2245238-80-4 | / | / |
| Lithium 4,6-Dichloropyridazine-3-carboxylate Hydrate | 2245111-15-1 | / | / |
我们能如何帮助您？
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →